Comparison of nanofiltration efficacy in reducing infectivity of centrifuged versus ultracentrifuged 263K scrapie-infected brain homogenates in "spiked" albumin solutions

Transfusion

Volumn 52, Issue 5, 2012, Pages 953-962

  Cardone, Franco ^a,b,c,d   Simoneau, Steve ^a,b,c,d   Arzel, Aude ^a,b,c,d   Puopolo, Maria ^a,b,c,d   Berardi, Vito Angelo ^a,b,c,d   Abdel Haq, Hanin ^a,b,c,d   Galeno, Roberta ^a,b,c,d   De Pascalis, Angela ^a,b,c,d   Sbriccoli, Marco ^a,b,c,d   Graziano, Silvia ^a,b,c,d   Valanzano, Angelina ^a,b,c,d   Porte, Pierre ^a,b,c,d   Diringer, Heino ^a,b,c,d   Brown, Paul ^a,b,c,d   Flan, Benoët ^a,b,c,d   Pocchiari, Maurizio ^a,b,c,d  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b CEA/DSV/iMETI/SEPIA ^*  (Germany)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^d LFB Laboratoire Français du Fractionnement et des Biotechnologies   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN ALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; BRAIN HOMOGENATE; CENTRIFUGATION; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; HAMSTER; HUMAN; INTERMETHOD COMPARISON; NANOFILTRATION; NONHUMAN; PRION; SCRAPIE; ULTRACENTRIFUGATION; VIRUS INFECTIVITY; VIRUS TRANSMISSION;

EID: 84861097622     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03425.x     Document Type: Article

References (66)

1. Knight R,. The risk of transmitting prion disease by blood or plasma products. Transfus Apher Sci 2010; 43: 387-91.
2. Lefrere JJ, Hewitt P,. From mad cows to sensible blood transfusion: the risk of prion transmission by labile blood components in the United Kingdom and in France. Transfusion 2009; 49: 797-812.
3. Coste J, Prowse C, Eglin R, Fang C,; Subgroup on TSE. A report on transmissible spongiform encephalopathies and transfusion safety. Vox Sang 2009; 96: 284-91.
4. Chohan G, Llewelyn C, Mackenzie J, Cousens S, Kennedy A, Will R, Hewitt P,. Variant Creutzfeldt-Jakob disease in a transfusion recipient: coincidence or cause? Transfusion 2010; 50: 1003-6.
5. Peden A, McCardle L, Head MW, Love S, Ward HJ, Cousens SN, Keeling DM, Millar CM, Hill FG, Ironside JW,. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16: 296-304.
6. Edgeworth JA, Farmer M, Sicilia A, Tavares P, Beck J, Campbell T, Lowe J, Mead S, Rudge P, Collinge J, Jackson GS,. Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet 2011; 377: 487-93.
7. Gregori L,. A prototype assay to detect vCJD-infected blood. Lancet 2011; 377: 444-6.
8. European Medicines Agency. CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products. EMEA/CPMP/BWP/2879/02/rev 2, 2010. [cited 2011 Oct 19]. Available from: URL http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/ 07/WC500095070.pdf
9. Flan B, Arrabal S,. Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal. Transfus Clin Biol 2007; 14: 51-62.
10. Burnouf T, Radosevich M, El-Ekiaby M, Satoh S, Sato T, Amin SN, Savidge GF, Goubran HA,. Nanofiltration of single plasma donations: feasibility study. Vox Sang 2003; 84: 111-9.
11. Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF, Caughey B,. The most infectious prion protein particles. Nature 2005; 437: 257-61.
12. Sasaki K, Minaki H, Iwaki T,. Development of oligomeric prion-protein aggregates in a mouse model of prion disease. J Pathol 2009; 219: 123-30.
13. Tixador P, Herzog L, Reine F, Jaumain E, Chapuis J, Le Dur A, Laude H, Béringue V,. The physical relationship between infectivity and prion protein aggregates is strain-dependent. PLoS Pathog 2010; 6: e1000859.
14. Kobayashi A, Satoh S, Ironside JW, Mohri S, Kitamoto T,. Type 1 and type 2 human PrPSc have different aggregation sizes in methionine homozygotes with sporadic, iatrogenic and variant Creutzfeldt-Jakob disease. J Gen Virol 2005; 86: 237-40.
15. Tzaban S, Friedlander G, Schonberger O, Horonchik L, Yedidia Y, Shaked G, Gabizon R, Taraboulos A,. Protease-sensitive scrapie prion protein in aggregates of heterogeneous sizes. Biochemistry 2002; 41: 12868-75.
16. Pastrana MA, Sajnani G, Onisko B, Castilla J, Morales R, Requena JR,. Isolation and characterization of a proteinase K-sensitive PrPSc fraction. Biochemistry 2006; 45: 15710-7.
17. Zou WQ, Puoti G, Xiao X, Yuan J, Qing L, Cali I, Shimoji M, Langeveld JP, Castellani R, Notari S, Crain B, Schmidt RE, Geschwind M, Dearmond SJ, Cairns NJ, Dickson D, Honig L, Torres JM, Mastrianni J, Capellari S, Giaccone G, Belay ED, Schonberger LB, Cohen M, Gambetti P,. et al. Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Ann Neurol 2010; 68: 162-72.
18. Berardi VA, Cardone F, Valanzano A, Lu M, Pocchiari M,. Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation. Transfusion 2006; 46: 652-8.
19. Kascsak RJ, Rubenstein R, Merz PA, Tonna-DeMasi M, Fersko R, Carp RI, Wisniewski HM, Diringer H,. Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol 1987; 61: 3688-93.
20. Pocchiari M, Casaccia P, Ladogana A,. Amphotericin B: a novel class of antiscrapie drugs. J Infect Dis 1989; 160: 795-802.
21. Kimberlin RH, Walker CA,. Characteristics of a short incubation model of scrapie in the golden hamster. J Gen Virol 1977; 34: 295-304.
22. Prusiner SB, Groth DF, Cochran SP, Masiarz FR, McKinley MP, Martinez HM,. Molecular properties, partial purification, and assay by incubation period measurements of the hamster scrapie agent. Biochemistry 1980; 19: 4883-91.
23. Reed J, Muench H,. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938; 27: 493-47.
24. Pocchiari M, Schmittinger S, Masullo C,. Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters. J Gen Virol 1987; 68: 219-23.
25. Dickinson AG,. Scrapie in sheep and goats. Front Biol 1976; 44: 209-41.
26. Casalone C, Zanusso G, Acutis P, Ferrari S, Capucci L, Tagliavini F, Monaco S, Caramelli M,. Identification of a second bovine amyloidotic spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob disease. Proc Natl Acad Sci U S A 2004; 101: 3065-70.
27. Kimberlin RH, Cole S, Walker CA,. Transmissible mink encephalopathy (TME) in Chinese hamsters: identification of two strains of TME and comparisons with scrapie. Neuropathol Appl Neurobiol 1986; 12: 197-206.
28. Nonno R, Di Bari MA, Cardone F, Vaccari G, Fazzi P, Dell'Omo G, Cartoni C, Ingrosso L, Boyle A, Galeno R, Sbriccoli M, Lipp HP, Bruce M, Pocchiari M, Agrimi U,. Efficient transmission and characterization of Creutzfeldt-Jakob disease strains in bank voles. PLoS Pathog 2006; 2: e12.
29. Bishop MT, Will RG, Manson JC,. Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties. Proc Natl Acad Sci U S A 2010; 107: 12005-10.
30. Parchi P, Cescatti M, Notari S, Schulz-Schaeffer WJ, Capellari S, Giese A, Zou WQ, Kretzschmar H, Ghetti B, Brown P,. Agent strain variation in human prion disease: insights from a molecular and pathological review of the National Institutes of Health series of experimentally transmitted disease. Brain 2010; 133: 3030-42.
31. Gambetti P, Cali I, Notari S, Kong Q, Zou WQ, Surewicz WK,. Molecular biology and pathology of prion strains in sporadic human prion diseases. Acta Neuropathol 2011; 121: 79-90.
32. Fraser H, Dickinson AG,. Scrapie in mice. Agent-strain differences in the distribution and intensity of grey matter vacuolation. J Comp Pathol 1973; 83: 29-40.
33. Safar J, Cohen FE, Prusiner SB,. Quantitative traits of prion strains are enciphered in the conformation of the prion protein. Arch Virol Suppl 2000; 16: 227-35.
34. Choi YP, Peden AH, Gröner A, Ironside JW, Head MW,. Distinct stability states of disease-associated human prion protein identified by conformation-dependent immunoassay. J Virol 2010; 84: 12030-8.
35. Kascsak RJ, Rubenstein R, Merz PA, Carp RI, Robakis NK, Wisniewski HM, Diringer H,. Immunological comparison of scrapie-associated fibrils isolated from animals infected with four different scrapie strains. J Virol 1986; 59: 676-83.
36. Parchi P, Strammiello R, Giese A, Kretzschmar H,. Phenotypic variability of sporadic human prion disease and its molecular basis: past, present, and future. Acta Neuropathol 2011; 121: 91-112.
37. Brown P, Cervenáková L, McShane LM, Barber P, Rubenstein R, Drohan WN,. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39: 1169-78.
38. Yunoki M, Tanaka H, Urayama T, Hattori S, Ohtani M, Ohkubo Y, Kawabata Y, Miyatake Y, Nanjo A, Iwao E, Morita M, Wilson E, MacLean C, Ikuta K,. Prion removal by nanofiltration under different experimental conditions. Biologicals 2008; 36: 27-36.
39. Yunoki M, Tanaka H, Urayama T, Kanai Y, Nishida A, Yoshikawa M, Ohkubo Y, Kawabata Y, Hagiwara K, Ikuta K,. Infectious prion protein in the filtrate even after 15 nm filtration. Biologicals 2010; 38: 311-3.
40. Tateishi J, Kitamoto T, Ishikawa G, Manabe S,. Removal of causative agent of Creutzfeldt-Jakob disease (CJD) through membrane filtration method. Membrane 1993; 18: 357-62.
41. Tateishi J, Kitamoto T, Ishikawa G, Manabe S, Yamaguchi K,. Removal of the prion protein using validatable filter (BMM). In:, Beuvery EC, Zeijlemaker WP, Griffiths JB, editors. Animal cell technology: development towards the 21st century. Dordrecht, the Netherlands: Kluwer Academic Publishers; 1995. p. 637-40.
42. Tateishi J, Kitamoto T, Mohri S, Satoh S, Sato T, Shepherd A, Macnaughton MR,. Scrapie removal using Planova virus removal filters. Biologicals 2001; 29: 17-25.
43. Diez JM, Caballero S, Belda F, Otegui M, Gajardo R, Jorquera JI,. Capacity of the manufacturing process of Flebogamma(®) DIF, a new human high purity intravenous immunoglobulin, to remove a TSE model-agent. Biologicals 2010; 38: 670-4.
44. You B, Aubin JT, Le-Hir G, Arzel A, Laude H, Flan B,. In vitro infectivity assay for prion titration for application to the evaluation of the prion removal capacity of biological products manufacturing processes. J Virol Methods 2010; 164: 1-6.
45. Brown P, Cervenakova L, Diringer H,. Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jakob disease. J Lab Clin Med 2001; 137: 5-13.
46. Bruce ME, McConnell I, Will RG, Ironside JW,. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet 2001; 358: 208-9.
47. Herzog C, Rivière J, Lescoutra-Etchegaray N, Charbonnier A, Leblanc V, Salès N, Deslys JP, Lasmézas CI,. PrPTSE distribution in a primate model of variant, sporadic, and iatrogenic Creutzfeldt-Jakob disease. J Virol 2005; 79: 14339-45.
48. Hunter N, Foster J, Chong A, McCutcheon S, Parnham D, Eaton S, MacKenzie C, Houston F,. Transmission of prion diseases by blood transfusion. J Gen Virol 2002; 83: 2897-905.
49. Houston F, Foster JD, Chong A, Hunter N, Bostock CJ,. Transmission of BSE by blood transfusion in sheep. Lancet 2000; 356: 999-1000.
50. Brown P, Rohwer RG, Dunstan BC, MacAuley C, Gajdusek DC, Drohan WN,. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998; 38: 810-6.
51. Casaccia P, Ladogana A, Xi YG, Pocchiari M,. Levels of infectivity in the blood throughout the incubation period of hamsters peripherally injected with scrapie. Arch Virol 1989; 108: 145-9.
52. Cervenakova L, Yakovleva O, McKenzie C, Kolchinsky S, McShane L, Drohan WN, Brown P,. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 2003; 43: 1687-94.
53. Diringer H,. Sustained viremia in experimental hamster scrapie. Arch Virol 1984; 82: 105-9.
54. Kuroda Y, Gibbs CJ Jr, Amyx HL, Gajdusek DC,. Creutzfeldt-Jakob disease in mice: persistent viremia and preferential replication of virus in low-density lymphocytes. Infect Immun 1983; 41: 154-61.
55. Brown P,. Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy. Haemophilia 2007; 13 Suppl 5: 33-40.
56. Murayama Y, Yoshioka M, Okada H, Takata M, Yokoyama T, Mohri S,. Urinary excretion and blood level of prions in scrapie-infected hamsters. J Gen Virol 2007; 88: 2890-8.
57. Gregori L, Kovacs GG, Alexeeva I, Budka H, Rohwer RG,. Excretion of transmissible spongiform encephalopathy infectivity in urine. Emerg Infect Dis 2008; 14: 1406-12.
58. Haley NJ, Seelig DM, Zabel MD, Telling GC, Hoover EA,. Detection of CWD prions in urine and saliva of deer by transgenic mouse bioassay. PLoS ONE 2009; 4: e4848.
59. Castilla J, Saá P, Soto C,. Detection of prions in blood. Nat Med 2005; 11: 982-5.
60. Orrú CD, Wilham JM, Raymond LD, Kuhn F, Schroeder B, Raeber AJ, Caughey B,. Prion disease blood test using immunoprecipitation and improved quaking-induced conversion. MBio 2011; 2: e00078-11.
61. Cardone F, Valanzano A, Abdel-Haq H, Graziano S, Sbriccoli M, Puopolo M, Pocchiari M, Sowemimo-Coker S,. Removal of exogenous (soluble) and endogenous infectivity from red cells by 22 layer variant of Pall leucotrap prion reduction filter. Prion 2009, Thessaloniki, 23-25 September 2009, abs P.2.69, p. 97.
62. Lescoutra-Etchegaray N, Comoy E, Sumian C, Deslys JP,. Removal of exogenous prion infectivity in leukoreduced red blood cells by Macopharma P-Capt filter. Prion 2009, Thessaloniki, 23-25 September 2009, abs P.2.59, p. 92.
63. Stamp JT, Brotherston JG, Zlotnik I, Mackay JM, Smith W,. Further studies on scrapie. J Comp Pathol 1959; 69: 268-80.
64. Gibbs CJ Jr, Gajdusek DC, Morris JA,. Viral characteristic of the scrapie agent in mice. In:, Gajdusek DC, Gibbs CJ Jr, Alpers M, editors. Slow, latent, and temperate virus infections. NINDB2 monograph no. 2. Washington (DC): US Government Printing Office; 1965. p. 195-202.
65. Pocchiari M, Macchi G, Peano S, Conz A,. Can potential hazard of Creutzfeldt-Jakob disease infectivity be reduced in the production of human growth hormone? Inactivation experiments with the 263K strain of scrapie. Arch Virol 1988; 98: 131-5.
66. Foster PR,. Removal of TSE agents from blood products. Vox Sang 2004; 87 Suppl 2: 7-10.